Search Results for “cancer” – Page 165 – media

Kite begins EU trial of CAR–T therapy

Kite Pharma has begun treating the first EU patients with its investigational CAR–T candidate, axicabtagene ciloleucel (axi-cel), in the safety expansion cohort of the ZUMA-1 trial.
- Source: pharmatimes
- 821
- August 10, 2017
CAR–T Clinical Trials Company Insight EU FDA
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 505
- August 4, 2017
Company Insight
10th International Conference on Clinical and Surgical Ophthalmology

Location: New South Wales, Australia Venue Address: DoubleTree by Hilton Beijing 168 Guang An Men Wai Avenue Xi Cheng District Beijing China Date: 07 Aug,2017 – 09 Aug,2017 Organizer: Sarika James Brief Conference Series LLC cordially invites you to participate at the 10th International Conference on Clinical and Surgical Ophthalmology to be held during August 07-09, 2017 at Beijing, China. The theme of the conference is “Exploring the novel research and trends in clinical and surgical ophthalmology” which focuses on the significance of vision and also explore the spectrum of latest technological developments in the field of Ophthalmology. Ophthalmology Conference 2017 maximizes the opportunity to interact with and learn from your peers from across the country and across the globe. Detailed Description: Conference Series LLC cordially invites you to participate at the 10th International Conference on Clinical and Surgical Ophthalmology to be held during August 07-09, 2017 at Beijing, China. ...
- Source: medical-events
- 616
- August 4, 2017
Clinical Exhibitions & Activities surgical
Johnson & Johnson Reports 2017 Second-Quarter Results

New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
- Source: www.jnj.com
- 593
- August 4, 2017
Company Insight
MRC links with UCB in antibody initiative

The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
- Source: pharmatimes
- 837
- August 4, 2017
antibody Company Insight Researches
EU OKs first-line use of AZ’ Faslodex

EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
- Source: pharmatimes
- 744
- July 28, 2017
breast cancer EU inhibitor New Approvals
Sensus gets Chinese regulatory approval for keloid device

US-based Sensus Healthcare has received approval from the China Food and Drug Administration (CFDA) to commercialise its keloid prevention and treatment device, SRT-100. The tool is designed to deliver a precise and calibrated dose of superficial radiation therapy to ensure a skin deep and safe treatment for patients. The low-dose radiation is intended to destroy keloid-causing non-malignant tumour cells, basal cell carcinoma and squamous cell carcinoma without the use of anaesthesia, risk of infection, scarring or the need for reconstructive plastic surgery. Sensus intends to introduce SRT-100 into the country’s market in the fourth quarter of this year through its Chinese partner Chindex Medical, which is a division of Fosun Pharma International. The device will focus on prevention and treatment of keloids associated with Cesarean sections (C-sections). Sensus Healthcare CEO Joe Sardano said: “CFDA clearance of the SRT-100 for the treatment and prevention of keloids is an important milestone for ...
- Source: Medicaldevice-network
- 447
- July 28, 2017
CFDA Company Insight keloid New Approvals
FDA clears BD’s immunological IVD system for commercialization

FDA has granted 510(k) clearance to Becton, Dickinson and Company’s (BD) in-vitro diagnostic (IVD) device, FACSLyric flow cytometer system.
- Source: Medicaldevice-network.com
- 522
- July 27, 2017
Clinical FDA immune New Approvals
Samsung launches new mobile full-body CT scanner

Samsung Electronics’ healthcare unit Samsung NeuroLogica has launched a new mobile, portable full-body computed tomography (CT) scanner, BodyTom Elite.
- Source: Medicaldevice-network-com
- 548
- July 26, 2017
Company Insight CT scanner New Approvals
Tumor-targeting MRI contrast developed, based on human protein

A team led by Gang Han, PhD, has designed a human protein-based, tumor-targeting Magnetic Resonance Imaging (MRI) contrast that can be easily cleared by the body. The discovery holds promise for clinical application, including early stage tumor detection because of the enhanced MRI contrast, according to Dr. Han, associate professor of biochemistry & molecular pharmacology at University of Massachusetts Medical School.
- Source: drugdu
- 421
- July 7, 2017
breast cancer Clinical New Approvals tumor

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.